Israeli-UK biotech Eleven Therapeutics is developing RNAi therapy that attacks the genetic structure of respiratory viruses such as SARS-COV-2. Eleven has just received a $9 million grant from the Gates Foundation.
Israeli-UK biotech Eleven Therapeutics is developing RNAi therapy that attacks the genetic structure of respiratory viruses such as SARS-COV-2. Eleven has just received a $9 million grant from the Gates Foundation.